CD163 and neoplasm: In addition, higher serum levels of the M2 marker CD163, and higher ratio of CD163+ cells to total macrophages [95] correlate with a higher tumor grade, worse progression-free survival, and early relapse of serous OC after first-line chemotherapy [96].